Skip to main content
RGNT logo

RGNT · Regentis Biomaterials Ltd.

Track RGNT — free
$2.13 +0.13 (+6.50%) At close · Aug 31
Market Cap
$14.05M
Shares
7.02M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.00 Open$2.10 Day$2.00–2.10 Available close range$1.28–9.40 Avg vol 30d86K Short int8K · 0.1% float · 1.0d Short vol46% DataDec 2025–Aug 2026

The closing range uses available history since Dec 4, 2025; less than a full year is stored.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 14.4 · calm Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 50-day avg −24%
below
RSI (14) 45
neutral
MACD trend Positive
52-week position 9%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +15%
trailing
6-month return −40%
trailing
YTD return −70%
this year
Relative strength −54%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+100% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.12% of float · ▼ -77.9% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
6 holders — 13F breadth
Squeeze score 20
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 648%
annualized · 1-yr
Max drawdown −83%
past year
ATR 11.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−24% Bearish
RSI (14)
45 Neutral
MACD trend
Positive Bullish
52-week position
9% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+100% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.12% of float · ▼ -77.9% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
6 holders — 13F breadth
Price context
position in its available closing range
Range low $1 Now $2 · 9% Range high $9
vs 50-day avg -24%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RGNT
Regentis Biomaterials Ltd.
this stock
$14.05M -70.3% 0.1%
ISRG
Intuitive Surgical Inc
$131.63B -34.2% +20.5% 42.8 2.0%
BDX
Becton Dickinson & Co
$51.24B +8.2% 3.4%
MDLN
Medline Inc.
$46.38B -16.0% +11.5% 2.8%
ALC
Alcon Inc
$34.83B -8.6% +10.5% 2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
6
% held
12.0%
Net QoQ
+293.9K sh
Top holder
Rosalind Advisors, Inc.
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
8.2K
Days to cover
1.0d
Change
-28.9K sh
View
Short Volume
Short vol %
46%
As of
Aug 31, 2026
Short Total
View
Fails to Deliver
FTD shares
3.3K
Value
$6.1K
As of
Aug 11, 2026
View
Off-Exchange
Off-exchange %
46.3%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-13.6M
EPS diluted
$-24.16
View
Filings
SEC Filings
Latest
6-K
Filed
Jul 20, 2026
This year
18
View
Exempt Offerings
Offering
$6.5M
Filed
Jun 25, 2026
View

Performance

5D 20D 120D MTD YTD
RGNT -4.8% +14.9% -40.2% +14.9% -70.3%
SPY +0.5% +3.0% +13.4% +3.0% +12.8%
vs SPY -5.2% +12.0% -53.7% +12.0% -83.2%
Key facts CIK 1912966 CUSIP M8211G108 13F (30d) 6 filings 6 filers Visit website Investor relations